trial

Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

NCTId NCT00669903
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 100 (actual)
Sponsored by AstraZeneca
Primary completion 2008-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
100 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-04
Primary completion
2008-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
AZD0328

Sponsors

AstraZenecaLead Sponsor

Sites

2 total
Garden Grove, United StatesGlendale, United States

Linked catalysts

1
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZ — primary completion2008-11

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE2
Primary Completion Date
2008-11
Status
TERMINATED
relationships
The graph out of here
drug
AZD0328
drug
lead_sponsor
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication